The Magstim Company

The Magstim Company

Magstim was founded in 1990 by neurophysiologist John Rothwell and a small group of engineers in Carmarthenshire, Wales, commercializing the transcranial magnetic stimulation (TMS) technology developed at the University of Sheffield. The firm's genesis lies in research-grade brain stimulation, providing neuroscientists with the first commercially reproducible tool to induce motor-evoked potentials by discharging a magnetic field through the scalp — a technique that became foundational in cognitive neuroscience and pre-surgical brain mapping. Magstim remains a privately held entity, with operational control based in Whitland, Wales, and a US commercial hub in Eden Prairie, Minnesota. The company's core intellectual property revolves around repetitive transcranial magnetic stimulation (rTMS) systems designed for both research and therapeutic applications. In the clinical domain, Magstim's Horizon TMS platform and its associated figure-of-eight coils are cleared by the FDA for treatment-resistant major depressive disorder, obsessive-compulsive disorder, and smoking cessation — making it one of only a handful of firms with a multi-indication neuromodulation franchise. The business model pairs capital equipment sales of the stimulator unit with a recurring revenue stream from single-use, patient-specific treatment coils, which are consumed on a per-session basis. Academic partnerships, including long-running collaborations with Harvard Medical School and the University of Tübingen, supply pipeline data for label expansion into bipolar depression and post-stroke motor recovery. Magstim operates a direct sales force in the US and UK supplemented by distributor networks across Europe, Japan, and China. The firm competes primarily with BrainsWay in the deep TMS segment and Neuronetics in the US psychiatry market. In 2018, Magstim acquired the Finnish navigated-TMS company Nexstim's diagnostic business, consolidating its research-line dominance. More recently, the company has funded a series of investigator-initiated trials exploring accelerated TMS protocols — delivering multiple treatments per day over a compressed timeframe — a delivery innovation that, if validated, could improve clinic throughput and strengthen the economic argument for psychiatry practices to adopt in-office TMS. Total headcount remains undisclosed. Magstim's structural differentiation lies in its dual-hemisphere market position: it is the default TMS brand in academic neuroscience labs while simultaneously holding the broadest FDA-cleared psychiatric portfolio among non-surgical neuromodulation platforms. This creates a built-in clinical pipeline, as psychiatrists who trained on Magstim equipment during residency are more likely to specify the brand in private practice. The company's patent estate, built around coil design and pulse waveform shaping, creates some barriers to entry, though core stimulator patents have begun to expire in key jurisdictions, shifting the competitive moat toward clinical data exclusivity and the installed base of consumable coil users.